期刊文献+

CD141与CD36对甲状腺功能减退症患者外周血管内皮功能的影响 被引量:2

Effects of monocyte CD141 and platelet CD36 on peripheral vascular endothelial function in patients with hypothyroidism
下载PDF
导出
摘要 目的:探讨单核细胞CD141及血小板CD36对甲状腺功能减退症患者(PWH)外周血管内皮功能的影响。方法:PWH组52例,40例健康体检者为对照组,流式细胞仪检测外周血单核细胞CD141及血小板CD36;彩色多普勒检测肱动脉血流介导的血管内皮舒张功能(FMD)。比较两组单核细胞表达CD141、血小板表达CD36的差异及FMD(%)的差异;Pearson法分析CD141及CD36与FMD(%)的相关性。结果:单核细胞CD141(%)PWH组为21.79±9.45,对照组为18.84±9.64,PWH组明显高于对照组(P<0.01);血小板CD36(%)PWH组为34.26±10.23,对照组为28.65±9.53,PWH组明显高于对照组(P<0.01)。FMD%PWH组为8.65±1.97,对照组为11.25±2.72,PWH组明显低于对照组(P<0.01)。CD141与FMD%存在负相关(r=-0.657,P<0.01);CD36与FMD%存在负相关(r=-0.557,P<0.01)。结论:PWH组单核细胞CD141及血小板CD36均明显高于对照组;CD141及CD36与血管内皮舒张功能均存在负相关。 Objective To investigate the effects of monocyte CD141 and platelet CD36 on peripheral vascular endothelial function(VEF) in patients with hypothyroidism(PWH). Methods The number of monocyte CD141 and platelet CD36 from 52 patients wtih PWH and 40 healthy persons(control group) was calculated by flow cytometry. VEF was detected in terms of brachial artery flow-mediated dilatation(FMD) using Doppler ultrasonography. The differences of expressions of monocyte CD141 and platelet CD36 were compared between the two groups, so was FMD. The association of monocyte CD141 and platelet CD36 with FMD(%) was analyzed by Pearson analysis. Results Expression of monocyte CD141(%) was significantly higher in the PWH group than in the control group(21.79 ± 9.45 vs. 18.84 ± 9.64, P〈0.001), so was expression of platelet CD36(%)(34.26 ± 10.23 vs. 28.65 ± 9.53, P〈0.001). FMD% was lower in the PWH group than in the control group(8.65 ± 1.97 vs. 11.25 ± 2.72, P〈0.001). CD141 was negatively correlated with FMD%(r =-0.657,P〈0.01), so was CD36(r =-0.557, P〈0.01). Conclusions Both monocyte CD141 and platelet CD36 are significantly higher in the PWH group than in the control group. CD141 and platelet CD36 are negatively related with VEF.
出处 《实用医学杂志》 CAS 北大核心 2016年第10期1595-1598,共4页 The Journal of Practical Medicine
基金 广西壮族自治区卫生计生委自筹经费科研课题(编号:z2014019)
关键词 CD141 CD36 甲状腺功能减退症 内皮细胞 CD141 CD36 Hypothyroidism Endothelial cells
  • 相关文献

参考文献12

  • 1CARNEMOLLA R, GREINEDER CF, CHACKO AM, et al. Platelet endothehal cell adhesion molec ule tm'geted oxidant-re- sistant mutant thrombomod ulin fusion protein with enhanced po- tency in vitro and in vivo [ J ]. J Pharmacol Exp Ther, 2013,347 (2) : 339-345.
  • 2CONWAY EM. Th:mmbomodulin and its role in inflammation [ J ]. Se min Immunopathol, 2012,34 ( 1 ) : 107-125.
  • 3CHAO TH, TSAI WC, CHEN JY, et al. Soluble thrombomod ulin is a paraerine anti-apoptotic factor for vascular endothelial protection [J]. Int J Cardiol, 2014, 172(2) :340-349.
  • 4PARK YM. CD36, a scavenger receptor implicated in atheroscle- rosis [J]. Exp Mol Med, 2014,46(6):e99.
  • 5TEJOVATHI B, SUCHITRA MM, SURESH V, et al. Associa- tion of lipid pemxidation with endothelial dysfunction in patients with overt hypothyroidism [J]. Exp Clin Endocrinol Diabetes, 2013,121 (5) : 306-309.
  • 6甲状腺疾病诊治指南——甲状腺功能减退症[J].中华内科杂志,2007,46(11):967-971. 被引量:358
  • 7CORRE333 MC, ANDERSON TJ, BENJAMIN EJ, et al. Guidelines for the ultrasound assessment of endotheli-aldepen- dent flow- mediated vasodilation of the braehial artery : a report of the International Brachial Artery Re-activity Task Force [J ]. J Am Coil Cardiol, 2002,39(2) :257-265.
  • 8LI YH, HSIEH CY, WANG DL, et al. Remodeling of carotid arteries is associated with increased expression of thrombomod Lin in a mouse transverse aortic constriction model [Jl. Thromb Haemost, 2008,97 (4) : 658 -664.
  • 9CHAO TH, TSAI WC, CHEN JY, et al. Soluble thrombomod ulin is a paracrine anti-apoptotic factor for vascular endothelial protection [ J ]. lnt J Calxtiol, 2014, 172 (2) : 340-349.
  • 10RAIFE TJ, DWYRE DM, STEVENS JW, et al. Human throm- bomod ulin knock-in mice reveal differential effects of humanthrombomod ulin on thrombosis and atherosclerosis [ J J. Arte- rioscler Thromb Vasc B iol, 2011,31 ( 11 ) : 2509-2517.

二级参考文献15

  • 1白耀.甲状腺病学:基础与临床.北京:科学技术文献出版社,2004:279-302.
  • 2滕卫平.甲状腺功能减退症//叶任高.内科学.6版.北京:人民卫生出版社,2005:736-738.
  • 3Davies TF, Larsen PR. Thyrotixicosis// Larsen PR, Kronenberg HM, Melmed S. Wlilliams textbook of endocrinology. 10th ed. Philadelphia: Saunders, 2002 : 374-424.
  • 4Wiersinga WM. Hypothyroidism and myxedema//DeGroot LJ, Jameson JL. Endocrinology. 4th ed. Philadelphia: Saunders, 2001:1491-1507.
  • 5Greenspan FS. The thyroid gland//Greenspan FS, Gardner DG. Basic and clinical endocrinology. New York: Lange /McGraw- Hill, 2001: 201-272.
  • 6Fisher DA. Disorders of the thyroid in the newborn and infant// Sperhng MA. Pediatric endocrinology. 2nd ed. Philadelphia: Sauners ,2002 : 161-186.
  • 7Ladenson PW, Singer AP, Ain KB, et al. American Thyroid Association guidelines for diction of thyroid dysfunction. Arch Intern Med, 2000, 160:1573-1575.
  • 8American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract, 2002,8:457-469.
  • 9Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med, 2006, 354:2783-2793.
  • 10Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol ( Oxf), 1995, 43:55-68.

共引文献357

同被引文献26

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部